Granexin for diabetic foot ulcer

NewsBot · Jul 17, 2013

Members do not see these Ads. Sign Up.
Press Release:
FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin™ Gel for the Treatment of Chronic Wounds and Scar Reduction
Positive Data on Novel Topical Peptide to be Presented at the International Gap Junction Conference 2013

FirstString Research, Inc. today announced that it will present positive data from three Phase 2 trials of GranexinTM Gel for the treatment of diabetic foot ulcers (DFUs), venous leg ulcers (VLUs) and for scar reduction at the upcoming International Gap Junction Conference (IGJC), July 13-18, 2013, in Charleston, SC. In each of the Phase 2 trials, GranexinTM Gel was well-tolerated and achieved the primary endpoint of the study with statistical significance. Patients treated with GranexinTM Gel demonstrated highly statistically significant improvements in mean percent wound closure at four and twelve weeks, as well as in incidence and time to 100% wound closure for DFUs and VLUs. A significant reduction in scar formation of surgical incisions following laparoscopic surgery was observed at the study end-point of nine months post-surgery. GranexinTM Gel contains a synthetic peptide, ACT1, which enhances wound healing through a multi-effect mechanism that promotes a healthy regenerative state in tissues.

“These data reinforce our belief that GranexinTM Gel has potential to become a first-in-class topical peptide for the treatment of chronic wounds and the reduction of scar formation.”

“Based on the favorable safety data and clinical activity demonstrated in these trials of GranexinTM Gel in DFUs and VLUs, we are in the process of finalizing plans to advance the Granexin program into pivotal Phase 3 studies,” said Gautam Ghatnekar, DVM, PhD, President and CEO of FirstString. “These data reinforce our belief that GranexinTM Gel has potential to become a first-in-class topical peptide for the treatment of chronic wounds and the reduction of scar formation.”

About the Granexin Gel™ Clinical Trials
FirstString Research is scheduled to present results from three separate Phase 2 trials of GranexinTM Gel in chronic wounds and scar reduction at the International Gap Junction Conference (IGJC). Each of the Phase 2 studies was randomized, controlled, multi-center, and blinded to evaluate the safety and efficacy of GranexinTM Gel for the treatment of VLUs and DFUs; and the reduction of scarring following laparoscopic surgery. In the twelve-week studies for the treatment of VLUs and DFUs, GranexinTM Gel (100μM ACT1) was administered three times in the first week, followed by weekly application for the following eleven weeks. To date, over 300 patients have participated in Phase 1 and Phase 2 clinical evaluations of GranexinTM Gel. GranexinTM Gel application resulted in highly significant increases in mean percent wound closure at four and twelve weeks as well as incidence of 100% wound closure, along with significantly reduced time for complete wound closure. In the nine-month study for the reduction of scarring following laparoscopic surgery, GranexinTM Gel (100μM ACT1) was administered once at wound closure and 24 hours post-surgery. GranexinTM Gel demonstrated statistically significant reduction in scarring as measured by Vancouver Scar Scoring (VSS) consisting of scar vascularity, pigmentation, pliability, and height at the study end-point of nine months post-surgery. In all studies, GranexinTM Gel was safe and well-tolerated with no drug-related systemic or local adverse events. Detailed results for the Phase 2 clinical trials will be published in peer-reviewed journals.

About Granexin™ Gel
Granexin GelTM contains ACT1, a synthetic peptide designed to mimic the C-terminus of the gap junction protein connexin 43 (Cx43), with high binding specificity to the tight junction associated protein zona occludens (ZO-1). Gap junctions and tight junctions are found in many cells throughout the body, including epithelial cells, which make up the skin and line other organs. Gap junctions connect the cytoplasms of adjacent cells, allowing free exchange of ions and molecules. Tight junctions form barriers between cells that are virtually impermeable by fluid. ACT1 is soluble, engineered to directly translocate within cells, and interacts with ZO-1, a known binding partner of the C-terminus of Cx43. The binding of the peptide to specific Cx43 C-terminus interaction domains such as PDZ-2 on ZO-1 serves to competitively inhibit its association with the Cx43 C-terminus, resulting in stabilized gap junctions and tight junctions. ACT1 also sequesters hemichannels (extracellular communicating channels) into gap junctions. This multi-effect mechanism – reducing hemichannel activity, promoting gap junctional communication, re-enforcing tight junction integrity – tempers excessive inflammation at the site of injury and promotes a healthy regenerative response. These activities result in the promotion of chronic wound healing and reduction of scarring. The clear, odorless, easy-to-apply topical formulation is also designed to provide a localized protective barrier against microbial colonization and a moist environment to promote natural autolytic debridement of necrotic tissue surrounding a wound. GranexinTM Gel has been evaluated in three Phase 2 trials for the treatment of diabetic foot ulcers, venous leg ulcers and the reduction of scarring following laparoscopic surgery.

About FirstString Research

FirstString Reseach, a clinical stage biotech company, is leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for wound healing, scar reduction, inflammation, and complex tissue regenerationࠀ The company is currently advancing GranexinTM Gel, a topical formulation containing the ACT1 peptide, for the treatment of chronic wounds and scar reduction, through clinical trials, with the goal to broaden the treatment options for patients suffering from morbidities associated with acute and chronic wounds. FirstString is also conducting preclinical studies with ACT1 for additional indications having high unmet therapeutic needs in a number of therapeutic segments that include ophthalmology, CNS injuries, cardiac injuries, organ transplants, acute lung injuries, and oncology.
Click to expand...

NewsBot · Feb 25, 2015

Topical administration of a Connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: A multicenter, randomized trial
Christina L. Grek PhD, G.M. Prasad MD, Vijay Viswanathan MD, David G. Armstrong DPM, MD, PhD, Robert G. Gourdie PhD and Gautam S. Ghatnekar DVM, PhD
Wound Repair and Regeneration; Accepted Article

Nonhealing neuropathic foot ulcers remain a significant problem in individuals with diabetes. The gap-junctional protein connexin43 (Cx43) has roles in dermal wound healing and targeting Cx43 signaling accelerates wound reepithelialization. In a prospective, randomized, multi-center clinical trial we evaluated the efficacy and safety of a peptide mimetic of the C-terminus of Cx43, ACT1, in accelerating the healing of chronic diabetic foot ulcers (DFUs) when incorporated into standard of care protocols. Adults with DFUs of at least four weeks duration were randomized to receive standard of care with or without topical application of ACT1. Primary outcome was mean percent ulcer reepithelialization and safety variables included incidence of treatment related adverse events and detection of ACT1 immunogenicity. ACT1 treatment was associated with a significantly greater reduction in mean percent ulcer area from baseline to 12 weeks (72.1% vs. 57.1%; p = 0.03). Analysis of incidence and median time-to-complete-ulcer closure revealed that ACT1 treatment was associated with a greater percentage of participants that reached 100% ulcer reepitheliazation and a reduced median time-to-complete-ulcer closure. No adverse events reported were treatment related, and ACT1 was not immunogenic. Treatment protocols that incorporate ACT1 may present a therapeutic strategy that safely augments the reepithelialization of chronic DFUs. This article is protected by copyright. All rights reserved.
Click to expand...

Admin2 · Feb 25, 2015

Related Threads:
Selinexor for diabetic foot ulcers
Aurix for diabetic foot ulcers
BioChaperone PDGF spray for diabetic foot ulcers
LeucoPatch™ for Diabetic Foot Ulcers
Pirfenidone for Diabetic Ulcers
KLOX BioPhotonic System for Diabetic Foot Ulcers
Brilacidin for diabetic foot wounds
EpiFix for diabetic foot ulcers
Lipo-PGE for diabetic foot ulcers
CollaRx for Diabetic Foot Ulcers
DermaPure for diabetic foot ulcers
MatriStem for diabetic foot ulcers
Resveratrol for diabetic foot ulcers
Santyl (colleganase) for diabetic foot ulcers

NewsBot · Aug 21, 2015

Abnormal connexin expression in human chronic wounds.
Sutcliffe JE et al
Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14064

BACKGROUND:
Regulated alterations in connexin expression have been shown to be integral to acute wound repair. Down-regulation of the gap junction protein connexin43 at the wound edge has been correlated to keratinocyte and fibroblast migration, whilst abnormal over-expression of connexin43 significantly perturbs healing as shown in the streptozotocin diabetic rodent impaired healing model.
OBJECTIVES:
We wished to examine the protein expression levels of connexin43, in addition to connexins 26 and 30,in a variety of human chronic wounds.
METHODS:
Wound edge punch biopsies and a matched arm control were taken from a cohort of patients with venous leg, diabetic foot or pressure ulcers. Wound connexin expression in each patient was compared to that in a matched, non-wounded arm punch. Tissue was sectioned, stained and imaged by confocal microscopy using identical parameters per patient to permit quantification.
RESULTS:
Epidermal connexin43, connexin26 and connexin30 and dermal connexin43 were discovered to be strikingly up-regulated in every ulcer from all three wound types, pointing to connexin up-regulation as a common feature between chronic wounds.
CONCLUSION:
This result supports efforts to target connexin43 to promote cell migration and wound healing in chronic ulcers.
Click to expand...

NewsBot · Jan 13, 2016

This clinical trial was just registered:
Safety Study to Examine the Systemic Exposure of Granexin? Gel After Topical Application to Diabetic Foot Ulcers

The purpose of this study is to determine the systemic exposure of Granexin? gel after topical application to human subjects' diabetic foot ulcers.
Click to expand...

Granexin for diabetic foot ulcer

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Admin2 Administrator Staff Member

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Pravibismane for diabetic foot infections

Homeopathy for Diabetic Foot Ulcers

Diabetic Foot Influencers on Twitter

Low Plasma Arginine among Patients with Diabetic Foot Ulcer

Epalrestat is effective in treating diabetic foot infection

Targeted exercises for the diabetic foot

Pranic Healing for Diabetic Foot Ulcer Management

Share This Page

Granexin for diabetic foot ulcer

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Admin2 Administrator Staff Member

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Pravibismane for diabetic foot infections

Homeopathy for Diabetic Foot Ulcers

Diabetic Foot Influencers on Twitter

Low Plasma Arginine among Patients with Diabetic Foot Ulcer

Epalrestat is effective in treating diabetic foot infection

Targeted exercises for the diabetic foot

Pranic Healing for Diabetic Foot Ulcer Management

Share This Page

Useful Searches